Form: 8-K

Current report

Documents

RESMED INC US false 0000943819 0000943819 2026-11-18 2026-11-18
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

November 18, 2026

Date of Report (Date of earliest event reported)

 

 

ResMed Inc.

(Exact Name of Registrant as Specified in Charter)

 

 

 

Delaware   001-15317   98-0152841

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

9001 Spectrum Center Boulevard

San Diego, California 92123

(Address of Principal Executive Offices) (Zip Code)

(858) 836-5000

(Registrant’s telephone number, including area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: 

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, $0.004 par value   RMD   NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

 

 
 


Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) Director Retirement

As previously disclosed on in its Current Report on Form 8-K, filed August 17, 2026, Ronald Taylor did not seek re-election at the 2026 annual meeting of stockholders of ResMed Inc. (the “Company”) held on November 18, 2026 (the “Annual Meeting”) and his term expired at the conclusion of the Annual Meeting. Effective November 18, 2026, the size of board of directors of the Company (the “Board”) was reduced from eleven (11) to ten (10) directors.

(e) FY2027 Performance-Based Restricted Stock Unit Awards

On November 19, 2026, the Compensation and Leadership Development Committee (the “CLDC”) of the Board approved a new form of Performance-Based Restricted Stock Unit Award Agreement for performance-based restricted stock units (“PSUs”) under the ResMed Inc. 2009 Incentive Award Plan, as amended and restated (the “Plan”), and approved fiscal year 2027 grants under the new form to the Company’s named executive officers. The PSUs granted in fiscal year 2027 under the new form reflect a change from the PSU design used in recent years, under which PSU awards vested based on the Company’s absolute total stockholder return (“TSR”) and relative TSR, respectively. The new design instead measures performance over three fiscal years against annual financial goals, subject to a relative TSR modifier measured over three years from the grant date (the “TSR Period”), as described below.

The number of PSUs earned under the fiscal year 2027 grants will be determined based on the Company’s performance against Adjusted EPS and Adjusted Revenue goals established by the CLDC for each of the Company’s three consecutive fiscal years beginning with fiscal year 2027 (each, an “Annual Measurement Period”). The “Performance Period” begins on the first day of the first Annual Measurement Period and ends on the later of (i) the last day of the final Annual Measurement Period and (ii) the last day of the TSR Period, subject to the TSR modifier. One-third of the target PSUs is allocated to each Annual Measurement Period and split equally between the two metrics. Performance at threshold, target and maximum for each metric results in a payout of 50%, 100% and 200%, respectively, of the target PSUs allocated to that metric, with no payout below threshold and linear interpolation between those levels.

Following the end of the Performance Period, the payout percentages for each metric are averaged across the three Annual Measurement Periods and weighted equally to determine the percentage of the target PSUs achieved. To determine the earned PSUs, that percentage is then multiplied by a relative TSR modifier ranging from 0.75 to 1.25, based on the percentile rank of the Company’s TSR relative to the companies in the S&P 500 Index over the TSR Period: 0.75 at or below the 25th percentile, 0.95 at the 50th percentile, 1.00 at the 60th percentile and 1.25 at or above the 75th percentile, with linear interpolation between those points. In no event may more than 200% of the target PSUs be earned. Earned PSUs will vest upon the CLDC’s certification of performance following the end of the Performance Period, subject to the executive’s continued service through the certification date, except as described below.

If an executive’s employment terminates due to death or disability, the PSUs will vest at 100% of target. Upon a qualifying retirement (after attaining age 60 with at least five years of continuous service, other than a termination for cause) at any time, or a termination by the Company without cause or resignation for good reason (other than in connection with a change in control) on or after the second anniversary of the grant date, the executive will remain eligible to vest in a prorated portion of the PSUs, based on the portion of the three-year service period completed and actual performance determined at the end of the Performance Period.

The PSUs provide for “double-trigger” vesting in connection with a change in control. If the PSUs are assumed, continued or substituted in a change in control occurring during the Performance Period, they convert into time-based restricted stock units equal to the greater of (i) the target number of PSUs and (ii) the number determined based on actual performance for completed Annual Measurement Periods, target performance for remaining Annual Measurement Periods and relative TSR through the change in control (subject to the 200% maximum). The converted units vest on the third anniversary of the grant date, subject to continued service, or earlier (a) in full upon death, disability or a qualifying termination without cause or resignation for good reason in connection with the change in control, or (b) as to a prorated portion upon a qualifying retirement, or a termination without cause or resignation for good reason on or after the second anniversary of the grant date, that is not in connection with the change in control. If the PSUs are not assumed, continued or substituted in connection with a change in control occurring during the Performance Period, they vest immediately prior to the change in control on the same greater-of basis.


Item 5.07.

Submission of Matters to a Vote of Security Holders.

On November 18, 2026, at the Annual Meeting, the Company’s stockholders (1) elected the ten nominees listed below to serve on the Board; (2) ratified the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2027; (3) approved, on an advisory basis, the compensation of the Company’s named executive officers.

 

     For      Against      Abstain      Broker
Non-Votes
 
Item of business 1: Elect the following ten directors, each to serve until the Company’s 2027 annual meeting and until their successors are elected and qualified:            

Carol Burt

     102,655,932        5,312,692        32,046        4,859,690  

Jan De Witte

     107,155,764        797,243        47,663        4,859,690  

Christopher DelOrefice

     106,567,544        1,382,705        50,421        4,859,690  

Karen Drexler

     104,524,805        3,429,001        46,864        4,859,690  

Michael Farrell

     101,422,535        6,199,356        378,779        4,859,690  

Peter Farrell

     106,311,677        1,652,905        36,088        4,859,690  

Harjit Gill

     105,871,373        2,092,804        36,493        4,859,690  

John Hernandez

     107,092,469        872,639        35,562        4,859,690  

Nicole Mowad-Nassar

     107,438,272        529,858        32,540        4,859,690  

Desney Tan

     107,140,584        824,343        35,743        4,859,690  

 

     For      Against      Abstain     

Broker
Non-Votes

Item of business 2: Ratify the Company’s selection of PricewaterhouseCoopers LLP as its independent registered public accounting firm for the fiscal year ending June 30, 2027.      109,994,316        2,836,375         29,669      N/A

 

     For      Against      Abstain      Broker
Non-Votes
 
Item of business 3: Approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Company’s proxy statement.      95,067,879        12,883,333         49,458        4,859,690  


Item 9.01.

Financial Statements and Exhibits.

 

(d)

Exhibits

 

Exhibits:

  

Description of Document

10.1*    Form of Performance-Based Restricted Stock Unit Award Agreement.
104    Cover Page Interactive Data File (embedded within the Inline XBRL, document).

 

*

Management contract or compensatory plan or arrangement


SIGNATURES

The Company has authorized the person whose signature appears below to sign this report on its behalf, in accordance with the Securities Exchange Act of 1934.

 

    RESMED INC.
    (registrant)
Date: November 19, 2026     By:  

/s/ Michael Rider

    Name:   Michael Rider
    Its:   Global General Counsel and Secretary